Development and Clinical Evaluation of a Novel <i>Ghrita</i> Formulation for Management of Autism Spectrum Disorder
Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder requiring integrative management approaches. Ayurvedic formulations such as Durvabrahmi Ghrita are Anubhuta Ayurvedic formulations composed of Cynodon dactylon (Durva) , Bacopa monnieri (Brahmi) , cow milk ( Go-dugdha ), and cow ghee ( Go-ghrita ), traditionally used for neuropsychiatric conditions and possessing cognitive-enhancing properties. Aim: The present study aimed to develop, standardise, and clinically evaluate Durvabrahmi Ghrita for the management of ASD. Methods: The formulation was prepared using the classical Sneha Kalpana method and evaluated by organoleptic, phytochemical, nutritional and HPTLC fingerprinting. A comparative clinical study was conducted on 40 ASD patients divided into two groups. Group A received oral Durvabrahmi Ghrita with Nasya (Nasal administration) and Shiropichu in addition to behaviour treatment, while Group B received only behaviour therapy. Statistical analysis was performed using paired and unpaired t-tests. Results: Physico-chemical parameters confirmed the formulation’s stability and quality, and HPTLC profiling revealed multiple bioactive phytoconstituents. Nutritional analysis showed the presence of 87.24% fat,4.06 % protein and 34.01% carbohydrates, indicating enrichment compared to plain ghee. Clinically, Group A showed statistically significant improvement (p Conclusion: Durvabrahmi Ghrita is a standardised, nutritionally enriched formulation with significant potential as an adjunct therapy in ASD management. Major Findings: The formulation demonstrated enhanced nutritional composition, confirmed phytoconstituents and significant clinical efficacy over behavioural therapy alone in improving cognitive and behavioural outcomes in ASD.